May 13, 2020Print(PDF/80KB)Corporate
Sumitomo Dainippon Pharma Announces Change in Board of Directors
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) announced today that in its meeting held on May 13, 2020, the Board of Directors appointed the following candidate for new member of the Board of Directors.
Change in the Members of the Board of Directors (as of June 23, 2020)
New Member of the Board of Directors
Yoshiharu Ikeda (currently Senior Executive Officer)
Note: The new member of the Board of Directors who will take office as of June 23, 2020 subject to the approval at the general shareholders' meeting scheduled for the same date.
Brief Personal History of candidate for new member of the Board of Directors
Yoshiharu Ikeda (Mr.) Birthdate: January 5, 1958
April 1985 Joined the former Sumitomo Pharmaceuticals Co., Ltd. June 2009 Senor Director, Global Corporate Strategy June 2010 Executive Officer, the Company Jan. 2012 Executive Vice President, Sunovion Pharmaceuticals Inc. April 2016 Senior Executive Officer (up to the present) April 2020 Regulatory Affairs; Medical Information; Medical Affairs; Corporate Regulatory Compliance & Quality Assurance Division; Technology Research & Development Division; Manufacturing Division
Executive Director, Corporate Regulatory Compliance & Quality Assurance Division
Deputy Head of Japan Business Unit (up to the present)